Cathie Wood's ARK ETFs have made a series of significant trades on Friday, February 14, 2025, continuing their dynamic investment strategy in the tech and biotech sectors. The most notable move was ...

On Thursday, Ark Invest, led by Cathie Wood, sold a chunk of its Robinhood shares. The sales come after the company posted ...

The firm has a 50 day moving average of $42.42 and a 200-day moving average of $25.29. Scholar Rock has a 12-month low of $6.76 and a 12-month high of $46.98. Insider Buying and Selling at Scholar ...

A closing highlight of the programme is the joint symposium for all European Amgen Scholars in Cambridge, UK. In addition to conducting hands-on research, you will attend workshops and events offering ...

Ark Invest purchased shares of CRISPR Therapeutics AG for both its ARK Genomic Revolution ETF ARKG and Ark Innovation ETF ARKK. The ARKG ETF bought 43,467 shares, while the ARKK ETF acquired ...

CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Scholar Rock is asking the U.S. Food and Drug Administration (FDA) to approve apitegromab, its experimental add-on therapy designed to boost motor function in people with spinal muscular atrophy (SMA) ...

The last time I wrote about Scholar Rock (NASDAQ:SRRK) it was with respect to a Seeking Alpha article entitled as "Scholar Rock: SMA Program Strides Forward With Positive Clinical Data".

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...